You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》大摩微降藥明生物(02269.HK)目標價至119.25元 評級「增持」
阿思達克 09-23 10:13
摩根士丹利發表報告,根據上半年業績和管理層指引,對藥明生物(02269.HK)今年短期收入增長預測降低2%,明年和後年分別降低6.7%和10%。該行對藥明生物今明兩年的毛利率預測亦由46%降至45.5%。 該行指,根據上半年趨勢,降低了對藥明生物的研發和營業費用的成本比率假設。因此對其今年的每股盈利預測上升3.1%,明年和後年每股盈利預測分別降2.9%和6.2%。 大摩表示,微降藥明生物目標價由119.8元降至119.25元,相當於預測今年市盈率77倍,估計於2021年至2024年純利複合增長率為38%,維持「增持」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account